{"alternate_names":["NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IX","NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IX"],"id":"38286","keywords":[],"medgen_id":"C4540265","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0060585\"}","{\"db\":\"OMIM\",\"id\":\"617721\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"191050.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IX\"}","{\"db\":\"OMIM\",\"id\":\"191050.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IX\"}","{\"db\":\"OMIM\",\"id\":\"617721\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE IX\"}","{\"db\":\"OMIM\",\"id\":\"617721\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE IX\"}","{\"db\":\"OMIM\",\"id\":\"617721\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DHMN9\"}","{\"db\":\"OMIM\",\"id\":\"617721\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMN9\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0060585\",\"ref_field\":\"name\"}"],"type":"Disease","alternate_symbols":["DHMN9","HMN9"],"name":"Neuronopathy, distal hereditary motor, type 9"}
{"symbol":"SBIDDS","alternate_names":["SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES"],"id":"36195","keywords":[],"medgen_id":"C4310689","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014944\"}","{\"db\":\"OMIM\",\"id\":\"617157\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"464288\"}","{\"db\":\"OMIM\",\"id\":\"610087.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"610087.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"610087.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"610087.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"610087.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"610087.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"610087.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"617157\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT STATURE, BRACHYDACTYLY, IMPAIRED INTELLECTUAL DEVELOPMENT, AND SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"617157\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Short stature, brachydactyly, intellectual developmental disability, and seizures"}
{"symbol":"CORD3","alternate_names":[],"id":"831","keywords":[],"medgen_id":"C1858806","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011395\"}","{\"db\":\"OMIM\",\"id\":\"604116\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1872\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10653\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cone-Rod+Dystrophy+3/1769\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604116\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"gard_id":"10653","name":"Cone-rod dystrophy 3"}
{"symbol":"CANVAS","alternate_names":[],"id":"16879","keywords":[],"medgen_id":"C3281223","attribute_content":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"614575\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"614575\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome"}
{"alternate_names":["Malignant melanoma","Skin cancer (melanoma)"],"id":"23374","keywords":["Neoplasm"],"medgen_id":"CN971653","attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002861\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002887\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006777\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007474\",\"type\":\"secondary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0005105\"}","{\"db\":\"MeSH\",\"id\":\"D008545\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002861\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Skin cancer (melanoma)\"}"],"type":"Disease","alternate_symbols":[],"name":"Melanoma"}
{"symbol":"CVID","alternate_names":["Common variable hypogamma-globulinemia"],"id":"37880","keywords":[],"medgen_id":"C2936664","public_definition":"Common variable immune deficiency (CVID) is a disorder that impairs the immune system. People with CVID are highly susceptible to infection from foreign invaders such as bacteria, or more rarely, viruses and often develop recurrent infections, particularly in the lungs, sinuses, and ears. Pneumonia is common in people with CVID. Over time, recurrent infections can lead to chronic lung disease. Affected individuals may also experience infection or inflammation of the gastrointestinal tract, which can cause diarrhea and weight loss. Abnormal accumulation of immune cells causes enlarged lymph nodes (lymphadenopathy) or an enlarged spleen (splenomegaly) in some people with CVID. Immune cells can accumulate in other organs, forming small lumps called granulomas.Approximately 25 percent of people with CVID have an autoimmune disorder, which occurs when the immune system malfunctions and attacks the body's tissues and organs. The blood cells are most frequently affected by autoimmune attacks in CVID; the most commonly occurring autoimmune disorders are immune thrombocytopenia, which is an abnormal bleeding disorder caused by a decrease in cell fragments involved in blood clotting called platelets, and autoimmune hemolytic anemia, which results in premature destruction of red blood cells. Other autoimmune disorders such as rheumatoid arthritis can occur. Individuals with CVID also have a greater than normal risk of developing certain types of cancer, including a cancer of immune system cells called non-Hodgkin lymphoma and less frequently, stomach (gastric) cancer.People with CVID may start experiencing signs and symptoms of the disorder anytime between childhood and adulthood; most people with CVID are diagnosed in their twenties or thirties. The life expectancy of individuals with CVID varies depending on the severity and frequency of illnesses they experience. Most people with CVID live into adulthood.There are many different types of CVID that are distinguished by genetic cause. People with the same type of CVID may have varying signs and symptoms.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015517\"}","{\"db\":\"OMIM\",\"id\":\"PS607594\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"1572\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6140\",\"ref_field\":\"gard_id\"}","{\"db\":\"SNOMED CT\",\"id\":\"191010004\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607594\",\"ref_field\":\"symbol\"}"],"type":"Finding","alternate_symbols":[],"gard_id":"6140","name":"Common variable immunodeficiency"}
{"symbol":"ARCL2D","alternate_names":["CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IID"],"id":"37748","keywords":[],"medgen_id":"C4479409","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0027451\"}","{\"db\":\"OMIM\",\"id\":\"617403\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"607027.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IID\"}","{\"db\":\"OMIM\",\"id\":\"607027.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IID\"}","{\"db\":\"OMIM\",\"id\":\"617403\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IID\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0027451\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617403\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Autosomal recessive cutis laxa type 2d"}
{"alternate_names":["Abnormality of lung morphology","Abnormality of the lungs","Abnormally shaped lung","Unusal lung shape"],"id":"31839","keywords":[],"medgen_id":"C4021760","attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002088\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002088\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormality of lung morphology\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002088\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormality of the lungs\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002088\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormally shaped lung\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002088\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Unusal lung shape\"}"],"type":"Finding","alternate_symbols":[],"name":"Abnormality of the lung"}
{"symbol":"ASGD8","alternate_names":[],"id":"36833","keywords":[],"medgen_id":"C4310622","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015017\"}","{\"db\":\"OMIM\",\"id\":\"617319\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617319\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Anterior segment dysgenesis 8"}
{"alternate_names":[],"id":"6200","keywords":[],"medgen_id":"C2931743","attribute_content":[],"xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Lactate+dehydrogenase+deficiency+type+A/4068\",\"ref_field\":\"name\"}"],"type":"Disease","alternate_symbols":[],"name":"Lactate dehydrogenase deficiency type A"}
{"symbol":"EDS","alternate_names":["ED syndrome"],"id":"6501","keywords":[],"medgen_id":"C0013720","public_definition":"Ehlers-Danlos syndrome is a group of disorders that affect connective tissues supporting the skin, bones, blood vessels, and many other organs and tissues. Defects in connective tissues cause the signs and symptoms of these conditions, which range from mildly loose joints to life-threatening complications.The various forms of Ehlers-Danlos syndrome have been classified in several different ways. Originally, 11 forms of Ehlers-Danlos syndrome were named using Roman numerals to indicate the types (type I, type II, and so on). In 1997, researchers proposed a simpler classification (the Villefranche nomenclature) that reduced the number of types to six and gave them descriptive names based on their major features. In 2017, the classification was updated to include rare forms of Ehlers-Danlos syndrome that were identified more recently. The 2017 classification describes 13 types of Ehlers-Danlos syndrome.An unusually large range of joint movement (hypermobility) occurs in most forms of Ehlers-Danlos syndrome, and it is a hallmark feature of the hypermobile type. Infants and children with hypermobility often have weak muscle tone (hypotonia), which can delay the development of motor skills such as sitting, standing, and walking. The loose joints are unstable and prone to dislocation and chronic pain. In the arthrochalasia type of Ehlers-Danlos syndrome, infants have hypermobility and dislocations of both hips at birth.Many people with the Ehlers-Danlos syndromes have soft, velvety skin that is highly stretchy (elastic) and fragile. Affected individuals tend to bruise easily, and some types of the condition also cause abnormal scarring. People with the classical form of Ehlers-Danlos syndrome experience wounds that split open with little bleeding and leave scars that widen over time to create characteristic \"cigarette paper\" scars. The dermatosparaxis type of the disorder is characterized by loose skin that sags and wrinkles, and extra (redundant) folds of skin may be present.Bleeding problems are common in the vascular type of Ehlers-Danlos syndrome and are caused by unpredictable tearing (rupture) of blood vessels and organs. These complications can lead to easy bruising, internal bleeding, a hole in the wall of the intestine (intestinal perforation), or stroke. During pregnancy, women with vascular Ehlers-Danlos syndrome may experience rupture of the uterus. Additional forms of Ehlers-Danlos syndrome that involve rupture of the blood vessels include the kyphoscoliotic, classical, and classical-like types.Other types of Ehlers-Danlos syndrome have additional signs and symptoms. The cardiac-valvular type causes severe problems with the valves that control the movement of blood through the heart. People with the kyphoscoliotic type experience severe curvature of the spine that worsens over time and can interfere with breathing by restricting lung expansion. A type of Ehlers-Danlos syndrome called brittle cornea syndrome is characterized by thinness of the clear covering of the eye (the cornea) and other eye abnormalities. The spondylodysplastic type features short stature and skeletal abnormalities such as abnormally curved (bowed) limbs. Abnormalities of muscles, including hypotonia and permanently bent joints (contractures), are among the characteristic signs of the musculocontractural and myopathic forms of Ehlers-Danlos syndrome. The periodontal type causes abnormalities of the teeth and gums.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020066\"}","{\"db\":\"OMIM\",\"id\":\"PS130000\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"98249\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6322\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"ehlers-danlos-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS130000\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"398114001\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"ehlers-danlos-syndrome\",\"ref_field\":\"public_definition\"}"],"type":"Disease","alternate_symbols":[],"gard_id":"6322","name":"Ehlers-Danlos syndrome"}
{"alternate_names":["Renal tubular defect","Renal tubular disease"],"id":"21437","keywords":[],"medgen_id":"C0151747","attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000124\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000124\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Renal tubular defect\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000124\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Renal tubular disease\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000124\",\"ref_field\":\"name\"}"],"type":"Finding","alternate_symbols":[],"name":"Renal tubular dysfunction"}
{"symbol":"SPGF16","alternate_names":["ACEPHALIC SPERMATOZOA SYNDROME"],"id":"36307","keywords":[],"medgen_id":"C4310674","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014961\"}","{\"db\":\"OMIM\",\"id\":\"617187\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617187\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ACEPHALIC SPERMATOZOA SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"617187\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Spermatogenic failure 16"}
{"symbol":"STGD1","alternate_names":["Juvenile onset macular degeneration","MACULAR DYSTROPHY WITH FLECKS, TYPE 1","STGD","Stargardt macular dystrophy"],"id":"3842","keywords":[],"medgen_id":"C1855465","public_definition":"Stargardt macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, Stargardt macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. In most people with Stargardt macular degeneration, a fatty yellow pigment (lipofuscin) builds up in cells underlying the macula. Over time, the abnormal accumulation of this substance can damage cells that are critical for clear central vision. In addition to central vision loss, people with Stargardt macular degeneration have problems with night vision that can make it difficult to navigate in low light. Some affected individuals also have impaired color vision. The signs and symptoms of Stargardt macular degeneration typically appear in late childhood to early adulthood and worsen over time.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009549\"}","{\"db\":\"MeSH\",\"id\":\"C535804\"}","{\"db\":\"OMIM\",\"id\":\"248200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"364055\"}","{\"db\":\"Orphanet\",\"id\":\"827\"}","{\"db\":\"OMIM\",\"id\":\"248200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MACULAR DYSTROPHY WITH FLECKS, TYPE 1\"}","{\"db\":\"OMIM\",\"id\":\"248200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"STGD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Stargardt+disease+1/9354\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"stargardt-macular-degeneration\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"248200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["CNGB3"],"name":"Stargardt disease 1"}
{"symbol":"CDG2M","alternate_names":["CDG IIm","CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm","CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm, SOMATIC MOSAIC","EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 22"],"id":"17835","keywords":[],"medgen_id":"C3806688","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010478\"}","{\"db\":\"OMIM\",\"id\":\"300896\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"356961\"}","{\"db\":\"OMIM\",\"id\":\"300896\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CDG IIm\"}","{\"db\":\"OMIM\",\"id\":\"300896\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm\"}","{\"db\":\"OMIM\",\"id\":\"314375.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm\"}","{\"db\":\"OMIM\",\"id\":\"314375.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm, SOMATIC MOSAIC\"}","{\"db\":\"OMIM\",\"id\":\"314375.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIm, SOMATIC MOSAIC\"}","{\"db\":\"OMIM\",\"id\":\"300896\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 22\"}","{\"db\":\"OMIM\",\"id\":\"314375.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 22\"}","{\"db\":\"OMIM\",\"id\":\"314375.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 22\"}","{\"db\":\"OMIM\",\"id\":\"314375.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 22\"}","{\"db\":\"OMIM\",\"id\":\"300896\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDGIIm\"}","{\"db\":\"OMIM\",\"id\":\"300896\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EIEE22\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12403\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010478\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300896\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["CDGIIm","EIEE22"],"gard_id":"12403","name":"SLC35A2-CDG"}
{"symbol":"EIEE11","alternate_names":[],"id":"15766","keywords":[],"medgen_id":"C3150987","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013388\"}","{\"db\":\"OMIM\",\"id\":\"613721\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1934\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+11/8339\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613721\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Early infantile epileptic encephalopathy 11"}
{"alternate_names":["Arakawa syndrome 1","Formiminoglutamic acidemia","Formiminoglutamicaciduria (FIGLU-uria)","Formiminotransferase deficiency syndrome"],"id":"1296","keywords":[],"medgen_id":"C0268609","public_definition":"Glutamate formiminotransferase deficiency is an autosomal recessive disorder and the second most common inborn error of folate metabolism. Features of a severe phenotype include elevated levels of formiminoglutamate (FIGLU) in the urine in response to histidine administration, megaloblastic anemia, and mental retardation. Features of a mild phenotype include high urinary excretion of FIGLU in the absence of histidine administration, mild developmental delay, and no hematologic abnormalities (summary by Hilton et al., 2003).","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009240\"}","{\"db\":\"OMIM\",\"id\":\"229100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"51208\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9279\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Glutamate+Formiminotransferase+Deficiency/3104\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"229100\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606806.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606806.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606806.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606806.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606806.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606806.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"59761008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"229100\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}"],"type":"Disease","alternate_symbols":[],"gard_id":"9279","name":"GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY"}
{"symbol":"EDSCLL","alternate_names":["EDS due to TNX deficiency","EHLERS-DANLOS SYNDROME, CLASSIC-LIKE","Ehlers-Danlos-like syndrome due to tenascin-X deficiency","TNX deficiency"],"id":"2075","keywords":[],"medgen_id":"C1848029","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011670\"}","{\"db\":\"OMIM\",\"id\":\"606408\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"230839\"}","{\"db\":\"OMIM\",\"id\":\"606408\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EHLERS-DANLOS SYNDROME, CLASSIC-LIKE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ehlers-Danlos-Like+Syndrome+due+to+Tenascin-X+Deficiency/2492\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ehlers-Danlos-like syndrome due to tenascin-X deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8507\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011670\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606408\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"gard_id":"8507","name":"Ehlers-Danlos syndrome due to tenascin-X deficiency"}
{"symbol":"FGS2","alternate_names":[],"id":"1281","keywords":[],"medgen_id":"C1845902","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010297\"}","{\"db\":\"OMIM\",\"id\":\"300321\",\"type\":\"MIM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9923\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"FG+Syndrome+2/2843\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300321\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"gard_id":"9923","name":"FG syndrome 2"}
{"symbol":"ARCL2C","alternate_names":["CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIC"],"id":"37752","keywords":[],"medgen_id":"C4479387","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0027462\"}","{\"db\":\"OMIM\",\"id\":\"617402\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"108746.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIC\"}","{\"db\":\"OMIM\",\"id\":\"108746.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIC\"}","{\"db\":\"OMIM\",\"id\":\"617402\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIC\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0027462\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617402\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Autosomal recessive cutis laxa type 2c"}
{"alternate_names":["Addison disease","Adrenal aplasia","Adrenal gland hypofunction","Hypoadrenocorticism familial"],"id":"13226","keywords":[],"medgen_id":"C1868690","public_definition":"Autoimmune Addison disease affects the function of the adrenal glands, which are small hormone-producing glands located on top of each kidney. It is classified as an autoimmune disorder because it results from a malfunctioning immune system that attacks the adrenal glands. As a result, the production of several hormones is disrupted, which affects many body systems.The signs and symptoms of autoimmune Addison disease can begin at any time, although they most commonly begin between ages 30 and 50. Common features of this condition include extreme tiredness (fatigue), nausea, decreased appetite, and weight loss. In addition, many affected individuals have low blood pressure (hypotension), which can lead to dizziness when standing up quickly; muscle cramps; and a craving for salty foods. A characteristic feature of autoimmune Addison disease is abnormally dark areas of skin (hyperpigmentation), especially in regions that experience a lot of friction, such as the armpits, elbows, knuckles, and palm creases. The lips and the inside lining of the mouth can also be unusually dark. Because of an imbalance of hormones involved in development of sexual characteristics, women with this condition may lose their underarm and pubic hair.Other signs and symptoms of autoimmune Addison disease include low levels of sugar (hypoglycemia) and sodium (hyponatremia) and high levels of potassium (hyperkalemia) in the blood. Affected individuals may also have a shortage of red blood cells (anemia) and an increase in the number of white blood cells (lymphocytosis), particularly those known as eosinophils (eosinophilia).Autoimmune Addison disease can lead to a life-threatening adrenal crisis, characterized by vomiting, abdominal pain, back or leg cramps, and severe hypotension leading to shock. The adrenal crisis is often triggered by a stressor, such as surgery, trauma, or infection.Individuals with autoimmune Addison disease or their family members can have another autoimmune disorder, most commonly autoimmune thyroid disease or type 1 diabetes.","attribute_content":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"240200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"85138\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Addison%27s+Disease/215\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"autoimmune-addison-disease\",\"ref_field\":\"public_definition\"}"],"type":"Disease","alternate_symbols":[],"name":"Addison's disease"}
{"symbol":"CWS3","alternate_names":[],"id":"17663","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014045\"}","{\"db\":\"Orphanet\",\"id\":\"201\"}"],"type":"Disease","alternate_symbols":[],"name":"Cowden syndrome 3"}
{"symbol":"TYRSN2","alternate_names":["Keratosis palmoplantaris with corneal dystrophy","Oculocutaneous tyrosinemia","Oregon type tyrosinemia","Richner Hanhart syndrome","TAT deficiency","Tyrosine aminotransferase deficiency","Tyrosine transaminase deficiency","Tyrosinemia type 2","Tyrosinosis oculocutaneous type"],"id":"5080","keywords":[],"medgen_id":"C0268487","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010160\"}","{\"db\":\"OMIM\",\"id\":\"276600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"28378\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Tyrosinemia+type+2/7282\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Tyrosinemia type 2\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3105\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010160\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"276600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"gard_id":"3105","name":"Tyrosinemia type II"}
{"symbol":"SPMM","alternate_names":["Scapuloperoneal muscular dystrophy","Scapuloperoneal myopathy, MYH7-related","Scapuloperoneal syndrome, myopathic type"],"id":"15910","keywords":[],"medgen_id":"C4759774","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008409\"}","{\"db\":\"OMIM\",\"id\":\"181430\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"437572\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Scapuloperoneal+myopathy%2C+MYH7-related/6428\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Scapuloperoneal myopathy, MYH7-related\"}","{\"db\":\"OMIM\",\"id\":\"181430\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SPMD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10313\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008409\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"181430\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["SPMD"],"gard_id":"10313","name":"MYH7-related late-onset scapuloperoneal muscular dystrophy"}
{"symbol":"CNM3","alternate_names":[],"id":"16744","keywords":[],"attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013736\"}","{\"db\":\"Orphanet\",\"id\":\"169189\"}","{\"db\":\"Genetic Alliance\",\"id\":\"MYOPATHY%2C+CENTRONUCLEAR%2C+3/8948\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614408\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Myopathy, centronuclear, 3"}
{"alternate_names":[],"id":"53557","keywords":[],"medgen_id":"C4016256","attribute_content":[],"xrefs":[],"type":"Disease","alternate_symbols":[],"name":"Susceptibility to leprosy and multibacillary leprosy"}
{"symbol":"JBTS36","alternate_names":[],"id":"43481","keywords":[],"medgen_id":"C5231493","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032902\"}","{\"db\":\"OMIM\",\"id\":\"618763\",\"type\":\"MIM\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0032902\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618763\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Joubert syndrome 36"}
{"alternate_names":["CVI","Cerebral visual impairment","Cortical blindness","Cortical/cerebral visual impairment"],"id":"17247","keywords":[],"medgen_id":"C4048268","attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000595\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CVI\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cerebral visual impairment\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cortical blindness\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cortical/cerebral visual impairment\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"name\"}"],"type":"Finding","alternate_symbols":[],"name":"Cortical visual impairment"}
{"symbol":"MCOPS1","alternate_names":["ANOP1","Lenz dysplasia","MAA (formerly)","MICROPHTHALMIA, SYNDROMIC 4","Microphthalmia Lenz type","Microphthalmia or anophthalmos with associated anomalies (formerly)","Syndromic microphthalmia type 1"],"id":"2799","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301552\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1378\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301694\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1521\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"medgen_id":"C0796016","attribute_content":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"568\"}","{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANOP1\"}","{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MICROPHTHALMIA, SYNDROMIC 4\"}","{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MAA\"}","{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MCOPS4\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia+syndromic+1/4784\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"lenz-microphthalmia-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"438504004\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"309800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["MAA","MCOPS4","NAA10"],"name":"Lenz microphthalmia syndrome"}
{"symbol":"BTHS","alternate_names":["3-methylglutaconicaciduria type II","Barth syndrome","CARDIOMYOPATHY, DILATED, X-LINKED FATAL INFANTILE","Cardioskeletal myopathy with neutropenia and abnormal mitochondria","Dilated cardiomyopathy 3A","Endomyocardial fibroelastosis","LEFT VENTRICULAR NONCOMPACTION, ISOLATED, X-LINKED","LEFT VENTRICULAR NONCOMPACTION, X-LINKED","MGA type II"],"id":"487","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301486\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1309\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25299040\",\"@Source\":\"PubMed\"},{\"$\":\"NBK247162\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"medgen_id":"C0574083","public_definition":"Barth syndrome is characterized in affected males by cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay, and distinctive facial gestalt (most evident in infancy); not all features may be present in a given affected male. Cardiomyopathy, which is almost always present before age five years, is typically dilated cardiomyopathy with or without endocardial fibroelastosis or left ventricular noncompaction; hypertrophic cardiomyopathy can also occur. Heart failure is a significant cause of morbidity and mortality; risk of arrhythmia and sudden death is increased. Neutropenia is most often associated with mouth ulcers, pneumonia, and sepsis. The nonprogressive myopathy predominantly affects the proximal muscles, and results in early motor delays. Prepubertal growth delay is followed by a postpubertal growth spurt with remarkable \"catch-up\" growth. Heterozygous females who have a normal karyotype are asymptomatic and have normal biochemical studies.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010543\"}","{\"db\":\"OMIM\",\"id\":\"302060\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"111\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010543\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Barth syndrome\"}","{\"db\":\"OMIM\",\"id\":\"300069\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CARDIOMYOPATHY, DILATED, X-LINKED FATAL INFANTILE\"}","{\"db\":\"OMIM\",\"id\":\"300183\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEFT VENTRICULAR NONCOMPACTION, ISOLATED, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300183\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEFT VENTRICULAR NONCOMPACTION, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300069\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDFI\"}","{\"db\":\"OMIM\",\"id\":\"300069\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMD3A\"}","{\"db\":\"OMIM\",\"id\":\"305300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EFE\"}","{\"db\":\"OMIM\",\"id\":\"305300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EMFE\"}","{\"db\":\"OMIM\",\"id\":\"300183\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"INVM\"}","{\"db\":\"OMIM\",\"id\":\"300183\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LVNCX\"}","{\"db\":\"OMIM\",\"id\":\"302060\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MGA2\"}","{\"db\":\"OMIM\",\"id\":\"302060\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MGCA2\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5890\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Barth+Syndrome/744\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"297231002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK247162\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"302060\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["CDFI","CMD3A","EFE","EMFE","INVM","LVNCX","MGA2","MGCA2"],"gard_id":"5890","name":"3-Methylglutaconic aciduria type 2"}
{"symbol":"FTDALS1","alternate_names":["Frontotemporal dementia with motor neuron disease 1"],"id":"1898","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301623\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1450\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25577942\",\"@Source\":\"PubMed\"},{\"$\":\"NBK268647\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"medgen_id":"C3888102","public_definition":"C9orf72-related amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is characterized by: Motor neuron disease, including upper or lower motor neuron dysfunction (or both) that may or may not fulfill criteria for the ALS phenotype; Frontotemporal lobar degeneration (FTLD), including progressive changes in behavior, executive dysfunction, and/or language impairment; and Some degree of parkinsonism (typically of the akinetic-rigid type without tremor that is levodopa unresponsive). Age at onset is usually 30-70 years (range: 27-85 years) irrespective of the presenting symptoms. Initial manifestations may be pure FTLD or pure ALS; additional symptoms may appear during the disease course. Life expectancy is highly variable and mainly associated with the clinical manifestations.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007105\"}","{\"db\":\"OMIM\",\"id\":\"105550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"275872\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007105\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Frontotemporal dementia with motor neuron disease 1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501377\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FTDALS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK268647\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"105550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["FTDALS"],"name":"Amyotrophic lateral sclerosis and/or frontotemporal dementia 1"}
{"alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"id":"1790","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","keywords":[],"medgen_id":"C0002986","public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"}]}"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"type":"Disease","alternate_symbols":[],"gard_id":"6400","name":"Fabry disease"}
{"symbol":"CMH1","alternate_names":["MYH7-Related Familial Hypertrophic Cardiomyopathy"],"id":"1311","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301559\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1385\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301725\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1768\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21267010\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHRQ, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"NBK248310\",\"@Source\":\"BookShelf\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","keywords":[],"medgen_id":"C3495498","public_definition":"Hypertrophic cardiomyopathy (HCM) is typically defined by the presence of unexplained left ventricular hypertrophy (LVH). Such LVH occurs in a non-dilated ventricle in the absence of other cardiac or systemic disease capable of producing the observed magnitude of increased LV wall thickness, such as pressure overload (e.g., long-standing hypertension, aortic stenosis) or storage/infiltrative disorders (e.g., Fabry disease, amyloidosis). The clinical manifestations of HCM range from asymptomatic LVH to progressive heart failure to sudden cardiac death (SCD), and vary from individual to individual even within the same family. Common symptoms include shortness of breath (particularly with exertion), chest pain, palpitations, orthostasis, presyncope, and syncope. Most often the LVH of HCM becomes apparent during adolescence or young adulthood, although it may also develop late in life, in infancy, or in childhood.","attribute_content":["{\"Attribute\":{\"$\":\"C0949658\",\"@Type\":\"CUI, rejected\"}}"],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008647\"}","{\"db\":\"OMIM\",\"id\":\"192600\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Familial+hypertrophic+cardiomyopathy+1/8382\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"192600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Familial hypertrophic cardiomyopathy 1"}
{"symbol":"CDG1P","alternate_names":["ALG11-CDG","CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip"],"id":"15690","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301507\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1332\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C3150913","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013349\"}","{\"db\":\"OMIM\",\"id\":\"613661\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"280071\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0013349\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ALG11-CDG\"}","{\"db\":\"OMIM\",\"id\":\"613661\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"OMIM\",\"id\":\"613666.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ip\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12396\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+disorder+of+glycosylation+type+1P/8052\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613661\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"gard_id":"12396","name":"Congenital disorder of glycosylation type 1P"}
{"symbol":"CDG2I","alternate_names":["CDG IIi","CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi"],"id":"10033","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301507\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1332\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C3150876","public_definition":"COG5-congenital disorder of glycosylation (COG5-CDG, formerly known as congenital disorder of glycosylation type IIi) is an inherited condition that causes neurological problems and other abnormalities. The pattern and severity of this disorder's signs and symptoms vary among affected individuals.Individuals with COG5-CDG typically develop signs and symptoms of the condition during infancy. These individuals often have weak muscle tone (hypotonia) and delayed development. Other neurological features include moderate to severe intellectual disability, poor coordination, and difficulty walking. Some affected individuals never learn to speak. Other features of COG5-CDG include short stature, an unusually small head size (microcephaly), and distinctive facial features, which can include ears that are set low and rotated backward, a short neck with a low hairline in the back, and a prominent nose. Less commonly, affected individuals can have hearing loss caused by changes in the inner ear (sensorineural hearing loss), vision impairment, damage to the nerves that control bladder function (a condition called neurogenic bladder), liver disease, and joint deformities (contractures).","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013325\"}","{\"db\":\"OMIM\",\"id\":\"613612\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"263487\"}","{\"db\":\"OMIM\",\"id\":\"613612\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CDG IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"606821.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"613612\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIi\"}","{\"db\":\"OMIM\",\"id\":\"613612\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDGIIi\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+disorder+of+glycosylation+type+2I/8055\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"cog5-congenital-disorder-of-glycosylation\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613612\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["CDGIIi","COG5-CDG (CDG-IIi)"],"name":"Congenital disorder of glycosylation type 2i"}
{"symbol":"GKD","alternate_names":["GK deficiency","GK1 deficiency"],"id":"1727","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301604\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1431\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C0268418","public_definition":"NR0B1-related adrenal hypoplasia congenita includes both X-linked adrenal hypoplasia congenita (X-linked AHC) and Xp21 deletion (previously called complex glycerol kinase deficiency). X-linked AHC is characterized by primary adrenal insufficiency and/or hypogonadotropic hypogonadism (HH). Adrenal insufficiency is acute infantile onset (average age 3 weeks) in approximately 60% of affected males and childhood onset (ages 1-9 years) in approximately 40%. HH typically manifests in a male with adrenal insufficiency as delayed puberty (i.e., onset age \u003e14 years) and less commonly as arrested puberty at about Tanner Stage 3. Rarely, X-linked AHC manifests initially in early adulthood as delayed-onset adrenal insufficiency, partial HH, and/or infertility. Heterozygous females very occasionally have manifestations of adrenal insufficiency or hypogonadotropic hypogonadism. Xp21 deletion includes deletion of NR0B1 (causing X-linked AHC) and GK (causing glycerol kinase deficiency), and in some cases deletion of DMD (causing Duchenne muscular dystrophy). Developmental delay has been reported in males with Xp21 deletion when the deletion extends proximally to include DMD or when larger deletions extend distally to include IL1RAPL1 and DMD.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010613\"}","{\"db\":\"OMIM\",\"id\":\"307030\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"408\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hyperglycerolemia/3554\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"124322002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1431\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"307030\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Deficiency of glycerol kinase"}
{"alternate_names":["Malignant melanoma, somatic"],"id":"18337","content":"{\"Citation\":[{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Gonzalez et al., 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23360189\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"SSP, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24129426\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"FDA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25096067\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NICE, 2012\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma\"},\"URL\":{\"$\":\"http://www.nice.org.uk/guidance/ta269/chapter/guidance\"}}]}","keywords":[],"medgen_id":"C0025202","public_definition":"Melanoma is a type of skin cancer that begins in pigment-producing cells called melanocytes. This cancer typically occurs in areas that are only occasionally sun-exposed; tumors are most commonly found on the back in men and on the legs in women. Melanoma usually occurs on the skin (cutaneous melanoma), but in about 5 percent of cases it develops in melanocytes in other tissues, including the eyes (uveal melanoma) or mucous membranes that line the body's cavities, such as the moist lining of the mouth (mucosal melanoma). Melanoma can develop at any age, but it most frequently occurs in people in their fifties to seventies and is becoming more common in teenagers and young adults.Melanoma may develop from an existing mole or other normal skin growth that becomes cancerous (malignant); however, many melanomas are new growths. Melanomas often have ragged edges and an irregular shape. They can range from a few millimeters to several centimeters across. They can also be a variety of colors: brown, black, red, pink, blue, or white.Most melanomas affect only the outermost layer of skin (the epidermis). If a melanoma becomes thicker and involves multiple layers of skin, it can spread to other parts of the body (metastasize).A large number of moles or other pigmented skin growths on the body, generally more than 25, is associated with an increased risk of developing melanoma. Melanoma is also a common feature of genetic syndromes affecting the skin such as xeroderma pigmentosum. Additionally, individuals who have previously had melanoma are nearly nine times more likely than the general population to develop melanoma again. It is estimated that about 90 percent of individuals with melanoma survive at least 5 years after being diagnosed.","attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012056\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012056\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"melanoma\",\"ref_field\":\"public_definition\"}"],"type":"Disease","alternate_symbols":[],"name":"Cutaneous melanoma"}
{"symbol":"CGD3","alternate_names":["CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE III","GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 3","GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF4 DEFICIENCY"],"id":"16061","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22876374\",\"@Source\":\"PubMed\"},{\"$\":\"NBK99496\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C3151409","public_definition":"Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder of phagocytes (neutrophils, monocytes, macrophages, and eosinophils) resulting from impaired killing of bacteria and fungi. CGD is characterized by severe recurrent bacterial and fungal infections and dysregulated inflammatory response resulting in granuloma formation and other inflammatory disorders such as colitis. Infections typically involve the lung (pneumonia), lymph nodes (lymphadenitis), liver (abscess), bone (osteomyelitis), and skin (abscesses or cellulitis); granulomas typically involve the genitourinary system (bladder) and gastrointestinal tract (often the pylorus initially, and later the esophagus, jejunum, ileum, cecum, rectum, and perirectal area). Some males with X-linked CGD have McLeod neuroacanthocytosis syndrome as the result of a contiguous gene deletion. CGD may present anytime from infancy to late adulthood; however, the vast majority of affected individuals are diagnosed before age five years. Use of antimicrobial prophylaxis and therapy has greatly improved overall survival.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013507\"}","{\"db\":\"OMIM\",\"id\":\"613960\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"379\"}","{\"db\":\"OMIM\",\"id\":\"613960\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE III\"}","{\"db\":\"OMIM\",\"id\":\"601488.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 3\"}","{\"db\":\"OMIM\",\"id\":\"601488.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 3\"}","{\"db\":\"OMIM\",\"id\":\"601488.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 3\"}","{\"db\":\"OMIM\",\"id\":\"601488.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 3\"}","{\"db\":\"OMIM\",\"id\":\"601488.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 3\"}","{\"db\":\"OMIM\",\"id\":\"601488.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 3\"}","{\"db\":\"OMIM\",\"id\":\"613960\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 3\"}","{\"db\":\"OMIM\",\"id\":\"613960\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF4 DEFICIENCY\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK99496\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613960\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III"}
{"symbol":"CGDX","alternate_names":["CYTOCHROME b-NEGATIVE GRANULOMATOUS DISEASE, CHRONIC, X-LINKED","GRANULOMATOUS DISEASE, CHRONIC, X-LINKED, SOMATIC MOSAIC"],"id":"1398","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22876374\",\"@Source\":\"PubMed\"},{\"$\":\"NBK99496\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C1844376","public_definition":"Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder of phagocytes (neutrophils, monocytes, macrophages, and eosinophils) resulting from impaired killing of bacteria and fungi. CGD is characterized by severe recurrent bacterial and fungal infections and dysregulated inflammatory response resulting in granuloma formation and other inflammatory disorders such as colitis. Infections typically involve the lung (pneumonia), lymph nodes (lymphadenitis), liver (abscess), bone (osteomyelitis), and skin (abscesses or cellulitis); granulomas typically involve the genitourinary system (bladder) and gastrointestinal tract (often the pylorus initially, and later the esophagus, jejunum, ileum, cecum, rectum, and perirectal area). Some males with X-linked CGD have McLeod neuroacanthocytosis syndrome as the result of a contiguous gene deletion. CGD may present anytime from infancy to late adulthood; however, the vast majority of affected individuals are diagnosed before age five years. Use of antimicrobial prophylaxis and therapy has greatly improved overall survival.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010600\"}","{\"db\":\"OMIM\",\"id\":\"306400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"379\"}","{\"db\":\"OMIM\",\"id\":\"306400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CYTOCHROME b-NEGATIVE GRANULOMATOUS DISEASE, CHRONIC, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300481.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, X-LINKED, SOMATIC MOSAIC\"}","{\"db\":\"OMIM\",\"id\":\"306400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CGD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chronic+granulomatous+disease%2C+x-linked/7978\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK99496\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"306400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["CGD","X-CGD"],"name":"Chronic granulomatous disease, X-linked"}
{"symbol":"CGD1","alternate_names":["CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE I","GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1","GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF1 DEFICIENCY","NCF1 DEFICIENCY","NEUTROPHIL CYTOSOL FACTOR 1 DEFICIENCY","SOC2 DEFICIENCY","SOLUBLE OXIDASE COMPONENT II DEFICIENCY","p47-PHOX DEFICIENCY"],"id":"1397","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22876374\",\"@Source\":\"PubMed\"},{\"$\":\"NBK99496\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C1856251","public_definition":"Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder of phagocytes (neutrophils, monocytes, macrophages, and eosinophils) resulting from impaired killing of bacteria and fungi. CGD is characterized by severe recurrent bacterial and fungal infections and dysregulated inflammatory response resulting in granuloma formation and other inflammatory disorders such as colitis. Infections typically involve the lung (pneumonia), lymph nodes (lymphadenitis), liver (abscess), bone (osteomyelitis), and skin (abscesses or cellulitis); granulomas typically involve the genitourinary system (bladder) and gastrointestinal tract (often the pylorus initially, and later the esophagus, jejunum, ileum, cecum, rectum, and perirectal area). Some males with X-linked CGD have McLeod neuroacanthocytosis syndrome as the result of a contiguous gene deletion. CGD may present anytime from infancy to late adulthood; however, the vast majority of affected individuals are diagnosed before age five years. Use of antimicrobial prophylaxis and therapy has greatly improved overall survival.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009309\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"379\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1\"}","{\"db\":\"OMIM\",\"id\":\"608512.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1\"}","{\"db\":\"OMIM\",\"id\":\"608512.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1\"}","{\"db\":\"OMIM\",\"id\":\"608512.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1\"}","{\"db\":\"OMIM\",\"id\":\"608512.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1\"}","{\"db\":\"OMIM\",\"id\":\"608512.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1\"}","{\"db\":\"OMIM\",\"id\":\"608512.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1\"}","{\"db\":\"OMIM\",\"id\":\"608512.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 1\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF1 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NCF1 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUTROPHIL CYTOSOL FACTOR 1 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SOC2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SOLUBLE OXIDASE COMPONENT II DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"p47-PHOX DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chronic+granulomatous+disease%2C+autosomal+recessive+cytochrome+b-positive%2C+type+I/7976\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK99496\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"233700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Chronic granulomatous disease, autosomal recessive cytochrome b-positive, type 1"}
{"symbol":"CGD4","alternate_names":["CGD DUE TO DEFICIENCY OF THE ALPHA SUBUNIT OF CYTOCHROME b","CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-NEGATIVE","CYBA DEFICIENCY","GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4"],"id":"1396","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22876374\",\"@Source\":\"PubMed\"},{\"$\":\"NBK99496\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C1856255","public_definition":"Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder of phagocytes (neutrophils, monocytes, macrophages, and eosinophils) resulting from impaired killing of bacteria and fungi. CGD is characterized by severe recurrent bacterial and fungal infections and dysregulated inflammatory response resulting in granuloma formation and other inflammatory disorders such as colitis. Infections typically involve the lung (pneumonia), lymph nodes (lymphadenitis), liver (abscess), bone (osteomyelitis), and skin (abscesses or cellulitis); granulomas typically involve the genitourinary system (bladder) and gastrointestinal tract (often the pylorus initially, and later the esophagus, jejunum, ileum, cecum, rectum, and perirectal area). Some males with X-linked CGD have McLeod neuroacanthocytosis syndrome as the result of a contiguous gene deletion. CGD may present anytime from infancy to late adulthood; however, the vast majority of affected individuals are diagnosed before age five years. Use of antimicrobial prophylaxis and therapy has greatly improved overall survival.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009308\"}","{\"db\":\"OMIM\",\"id\":\"233690\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"379\"}","{\"db\":\"OMIM\",\"id\":\"233690\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CGD DUE TO DEFICIENCY OF THE ALPHA SUBUNIT OF CYTOCHROME b\"}","{\"db\":\"OMIM\",\"id\":\"233690\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-NEGATIVE\"}","{\"db\":\"OMIM\",\"id\":\"233690\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CYBA DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233690\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"OMIM\",\"id\":\"608508.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 4\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Granulomatous+disease%2C+chronic%2C+autosomal+recessive%2C+cytochrome+b-negative/8493\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK99496\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"233690\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Granulomatous disease, chronic, autosomal recessive, cytochrome b-negative"}
{"symbol":"CGD2","alternate_names":["CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE II","GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2","GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF2 DEFICIENCY","NCF2 DEFICIENCY","NEUTROPHIL CYTOSOL FACTOR 2 DEFICIENCY","p67-PHOX DEFICIENCY"],"id":"5212","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22876374\",\"@Source\":\"PubMed\"},{\"$\":\"NBK99496\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C1856245","public_definition":"Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder of phagocytes (neutrophils, monocytes, macrophages, and eosinophils) resulting from impaired killing of bacteria and fungi. CGD is characterized by severe recurrent bacterial and fungal infections and dysregulated inflammatory response resulting in granuloma formation and other inflammatory disorders such as colitis. Infections typically involve the lung (pneumonia), lymph nodes (lymphadenitis), liver (abscess), bone (osteomyelitis), and skin (abscesses or cellulitis); granulomas typically involve the genitourinary system (bladder) and gastrointestinal tract (often the pylorus initially, and later the esophagus, jejunum, ileum, cecum, rectum, and perirectal area). Some males with X-linked CGD have McLeod neuroacanthocytosis syndrome as the result of a contiguous gene deletion. CGD may present anytime from infancy to late adulthood; however, the vast majority of affected individuals are diagnosed before age five years. Use of antimicrobial prophylaxis and therapy has greatly improved overall survival.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009310\"}","{\"db\":\"OMIM\",\"id\":\"233710\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"379\"}","{\"db\":\"OMIM\",\"id\":\"233710\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CGD, AUTOSOMAL RECESSIVE CYTOCHROME b-POSITIVE, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"233710\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"608515.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 2\"}","{\"db\":\"OMIM\",\"id\":\"233710\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GRANULOMATOUS DISEASE, CHRONIC, DUE TO NCF2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233710\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NCF2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233710\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUTROPHIL CYTOSOL FACTOR 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"233710\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"p67-PHOX DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chronic+granulomatous+disease%2C+autosomal+recessive+cytochrome+b-positive%2C+type+II/7977\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK99496\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"233710\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Chronic granulomatous disease, autosomal recessive cytochrome b-positive, type 2"}
{"symbol":"MSUD3","alternate_names":["DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY","Dihydrolipoamide Dehydrogenase (E3) Deficiency","Dihydrolipoamide Dehydrogenase E3 Deficiency","E3 DEFICIENCY","MAPLE SYRUP URINE DISEASE, TYPE III"],"id":"9028","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25032271\",\"@Source\":\"PubMed\"},{\"$\":\"NBK220444\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"CN043137","public_definition":"The phenotypes of dihydrolipoamide dehydrogenase (DLD) deficiency are an overlapping continuum that ranges from early-onset neurologic manifestations to adult-onset liver involvement and, rarely, a myopathic presentation. Early-onset DLD deficiency typically manifests in infancy as hypotonia with lactic acidosis. Affected infants frequently do not survive their initial metabolic decompensation, or die within the first few years of life during a recurrent metabolic decompensation. Children who live beyond the first two to three years frequently exhibit growth deficiencies and residual neurologic deficits (intellectual disability, spasticity, ataxia, and seizures). In contrast, isolated liver involvement can present as early as the neonatal period and as late as the third decade. Evidence of liver injury/failure is preceded by nausea and emesis and frequently associated with encephalopathy and/or coagulopathy. Acute metabolic episodes are frequently associated with lactate elevations, hyperammonemia, and hepatomegaly. With resolution of the acute episodes affected individuals frequently return to baseline with no residual neurologic deficit or intellectual disability. Liver failure can result in death, even in those with late-onset disease. Individuals with the myopathic presentation may experience muscle cramps, weakness, and an elevated creatine kinase.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009529\"}","{\"db\":\"OMIM\",\"id\":\"246900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2394\"}","{\"db\":\"Orphanet\",\"id\":\"765\"}","{\"db\":\"OMIM\",\"id\":\"238331.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"238331.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"246900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"246900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"E3 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"246900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MAPLE SYRUP URINE DISEASE, TYPE III\"}","{\"db\":\"OMIM\",\"id\":\"246900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DLDD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3263\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Maple+syrup+urine+disease+type+1B/4456\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK220444\",\"ref_field\":\"public_definition\"}"],"type":"Disease","alternate_symbols":["DLDD"],"gard_id":"3263","name":"Maple syrup urine disease, type 3"}
{"symbol":"MMDS5","alternate_names":[],"id":"37982","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31580634\",\"@Source\":\"PubMed\"},{\"$\":\"NBK547304\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C4539919","public_definition":"ISCA1-related multiple mitochondrial dysfunctions syndrome (ISCA1-MMDS) is a severe neurodegenerative condition typically characterized by either no attainment of developmental milestones or very early loss of achieved milestones, seizures in early infancy, development of spasticity with exaggerated deep tendon reflexes, nystagmus, and risk for sensorineural hearing loss. Affected individuals may also demonstrate elevated blood lactate levels with an elevated lipid-lactate peak on brain MR spectroscopy. Further brain MRI findings may include extensive cerebral and cerebellar deep white matter hyperintensities, marked dilatation of the cerebral ventricles, and pachygyria. Prognosis is poor and most individuals succumb to an intercurrent illness in early childhood.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0033282\"}","{\"db\":\"OMIM\",\"id\":\"617613\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"611006.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611006.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617613\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK547304\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617613\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"MULTIPLE MITOCHONDRIAL DYSFUNCTIONS SYNDROME 5"}
{"symbol":"ARB","alternate_names":[],"id":"491","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301346\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1167\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22234150\",\"@Source\":\"PubMed\"}}]}","keywords":[],"medgen_id":"C3888198","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012733\"}","{\"db\":\"OMIM\",\"id\":\"611809\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139455\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bestrophinopathy%2C+autosomal+recessive/7813\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611809\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Bestrophinopathy, autosomal recessive"}
{"symbol":"VRCP","alternate_names":["Autosomal dominant Vitreoretinochoroidopathy","VITREORETINOCHOROIDOPATHY WITH MICROCORNEA, GLAUCOMA, AND CATARACT","VITREORETINOCHOROIDOPATHY, AUTOSOMAL DOMINANT, WITH NANOPHTHALMOS","VRCP autosomal dominant","Vitreoretinochoroidopathy dominant"],"id":"6115","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301346\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1167\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2012\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22234150\",\"@Source\":\"PubMed\"}}]}","keywords":[],"medgen_id":"C3888099","public_definition":"Autosomal dominant vitreoretinochoroidopathy (ADVIRC) is a disorder that affects several parts of the eyes, including the clear gel that fills the eye (the vitreous), the light-sensitive tissue that lines the back of the eye (the retina), and the network of blood vessels within the retina (the choroid). The eye abnormalities in ADVIRC can lead to varying degrees of vision impairment, from mild reduction to complete loss, although some people with the condition have normal vision.The signs and symptoms of ADVIRC vary, even among members of the same family. Many affected individuals have microcornea, in which the clear front covering of the eye (cornea) is small and abnormally curved. The area behind the cornea can also be abnormally small, which is described as a shallow anterior chamber. Individuals with ADVIRC can develop increased pressure in the eyes (glaucoma) or clouding of the lens of the eye (cataract). In addition, some people have breakdown (degeneration) of the vitreous or the choroid.A characteristic feature of ADVIRC, visible with a special eye exam, is a circular band of excess coloring (hyperpigmentation) in the retina. This feature can help physicians diagnose the disorder. Affected individuals may also have white spots on the retina.","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008662\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"263347\"}","{\"db\":\"Orphanet\",\"id\":\"3086\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VITREORETINOCHOROIDOPATHY WITH MICROCORNEA, GLAUCOMA, AND CATARACT\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VITREORETINOCHOROIDOPATHY, AUTOSOMAL DOMINANT, WITH NANOPHTHALMOS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Vitreoretinochoroidopathy+dominant/7409\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Vitreoretinochoroidopathy dominant\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ADVIRC\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5507\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneTests\",\"id\":\"319390\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"autosomal-dominant-vitreoretinochoroidopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"193220\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["ADVIRC"],"gard_id":"5507","name":"Vitreoretinochoroidopathy"}
{"symbol":"ODCRCS","disease_mechanism_id":"273","alternate_names":["TOOTH AGENESIS-COLORECTAL CANCER SYNDROME"],"id":"5670","disease_mechanism":"loss of function","keywords":["Hereditary cancer syndrome","Neoplasm"],"medgen_id":"C1837750","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012075\"}","{\"db\":\"OMIM\",\"id\":\"608615\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"300576\"}","{\"db\":\"OMIM\",\"id\":\"608615\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TOOTH AGENESIS-COLORECTAL CANCER SYNDROME\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000324342\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522383\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528518\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528654\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528909\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591173\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Oligodontia-colorectal+cancer+syndrome/9037\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608615\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"Oligodontia-colorectal cancer syndrome"}
{"symbol":"CRC","disease_mechanism_id":"273","alternate_names":["COLON CANCER","Familial colorectal cancer"],"id":"986","content":"{\"Citation\":[{\"@Abbrev\":\"EGAPP, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2743612\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"AMA/NCHPEG, 2012\",\"@Type\":\"Suggested Reading\",\"URL\":{\"$\":\"http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf\"}}]}","disease_mechanism":"loss of function","keywords":[],"medgen_id":"CN280943","attribute_content":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"114500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COLON CANCER\"}","{\"db\":\"OMIM\",\"id\":\"191170.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COLON CANCER\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Familial+Colorectal+Cancer/2734\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Familial colorectal cancer\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000321103\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000330058\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000333054\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501400\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501401\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501402\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501424\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508787\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508788\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508789\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508790\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508791\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508792\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508793\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508794\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508795\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508796\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508797\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508798\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508803\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509789\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510423\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512828\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515774\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519254\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519256\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519258\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519260\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519489\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519490\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520080\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520394\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522383\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522559\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527981\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527982\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527983\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527984\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528654\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530028\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530202\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552183\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552245\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552303\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558503\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562230\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569958\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570011\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591173\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591213\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"OMIM\",\"id\":\"191170.0038\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"516030.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"516030.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"516030.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"114500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":[],"name":"COLORECTAL CANCER"}
{"symbol":"RB1","disease_mechanism_id":"273","alternate_names":["Eye cancer, retinoblastoma","RETINOBLASTOMA, SOMATIC","Retina tumor"],"id":"6463","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301625\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1452\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ASHG/ACMG, 1995\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"1801355\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111019\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061998\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","disease_mechanism":"loss of function","keywords":["Hereditary cancer syndrome"],"medgen_id":"C0035335","mode_of_inheritance":"Both sporadic and heritable forms are tested.","public_definition":"Retinoblastoma is a malignant tumor of the developing retina that occurs in children, usually before age five years. Retinoblastoma develops from cells that have cancer-predisposing variants in both copies of RB1. Retinoblastoma may be unifocal or multifocal. About 60% of affected individuals have unilateral retinoblastoma with a mean age of diagnosis of 24 months; about 40% have bilateral retinoblastoma with a mean age of diagnosis of 15 months. Heritable retinoblastoma is an autosomal dominant susceptibility for retinoblastoma. Individuals with heritable retinoblastoma are also at increased risk of developing non-ocular tumors.","attribute_content":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009919\",\"type\":\"primary\"}","{\"db\":\"MeSH\",\"id\":\"D012175\"}","{\"db\":\"OMIM\",\"id\":\"180200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"790\"}","{\"db\":\"OMIM\",\"id\":\"614041.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RETINOBLASTOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"614041.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RETINOBLASTOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"614041.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RETINOBLASTOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"614041.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RETINOBLASTOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"614041.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RETINOBLASTOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"614041.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RETINOBLASTOMA, SOMATIC\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009919\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Retina tumor\"}","{\"db\":\"OMIM\",\"id\":\"180200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RB\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000324949\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000333054\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500108\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500594\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501237\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502479\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502480\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502581\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518780\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521639\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521663\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522559\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528909\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552478\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553202\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"GeneTests\",\"id\":\"2161\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Retinoblastoma/6282\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009919\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1452\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"180200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["RB"],"name":"Retinoblastoma"}
{"symbol":"CS","disease_mechanism_id":"274","alternate_names":["Cowden","Cowden disease","Cowden syndrome 2","Cowden's disease","Cowden's syndrome","Cowden-like syndrome","MACROCEPHALY, PSEUDOPAPILLEDEMA, AND MULTIPLE HEMANGIOMATA","Multiple hamartoma syndrome","RUVALCABA-MYHRE-SMITH SYNDROME"],"id":"33122","content":"{\"Citation\":[{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NCCN, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25190698\",\"@Source\":\"PubMed\"}}]}","disease_mechanism":"gain of function","keywords":["Hereditary cancer syndrome","PTEN HAMARTOMA TUMOR SYNDROME"],"medgen_id":"C0018553","attribute_content":[],"xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0016063\"}","{\"db\":\"OMIM\",\"id\":\"PS158350\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"201\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0016063\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cowden disease\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cowden-like+syndrome/8104\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cowden-like syndrome\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MACROCEPHALY, PSEUDOPAPILLEDEMA, AND MULTIPLE HEMANGIOMATA\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RUVALCABA-MYHRE-SMITH SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BBRS\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BZS\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CD\"}","{\"db\":\"OMIM\",\"id\":\"612359\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CWS2\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PHTS\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RMSS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512190\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515803\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520069\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520394\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552107\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552245\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557801\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558905\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6202\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"keywords\",\"ref_field_element\":\"PTEN HAMARTOMA TUMOR SYNDROME\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cowden+Syndrome/1947\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"cowden-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"58037000\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"158350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"type":"Disease","alternate_symbols":["BBRS","BZS","CD","CWS2","PHTS","RMSS"],"gard_id":"6202","name":"Cowden syndrome"}
